Bill > HB4544

This bill establishes a Prescription Drug Cost and Affordability Review Act to create a new Prescription Drug Affordability Board and Stakeholder Council aimed at managing and controlling prescription drug prices in Michigan. The board will consist of 5 members appointed by the governor who have expertise in healthcare economics, policy, and clinical medicine, and will be tasked with selecting and reviewing prescription drug products that meet certain cost criteria, such as high wholesale acquisition costs or significant price increases. The board can establish upper payment limits for drugs that create affordability challenges, which will be binding on healthcare purchasers and insurers. A complementary 21-member Stakeholder Council will be created to provide input and assist the board, representing diverse stakeholders including manufacturers, employers, healthcare providers, and patient advocacy groups. The board must submit annual reports to the legislature about drug price trends and may conduct studies on generic drug pricing and potential impacts. The bill includes strict conflict of interest provisions for board and council members and establishes a Prescription Drug Affordability Fund to support the board's operations. Importantly, any implementation of the act is subject to legislative appropriation, and the board is given rulemaking authority to carry out its functions.

Government Affairs

https://legislature.mi.gov/Bills/Bill?ObjectName=2025-HB-4544